Vator Securities advises ZignSec on 9m Directed Share Issue
ZignSec is a technology group in the rapidly growing RegTech industry. The company provides a SaaS platform with real-time digital customer knowledge and ID verification solutions with global reach.
The solutions are used by companies who in turn can optimise their processes to “onboard” both business customers and consumers while ensuring compliance with ever-changing local and global regulatory requirements for Know Your Customer (KYC) and Anti Money Laundering (AML).
read more
Vator Securities advises WntResearch on 56 MSEK Rights Issue
WntResearch is an oncology biotech company that develops new therapies to counteract the development of cancer metastases. The company’s research is focused on studying the endogenous protein WNT5A, which has been shown in scientific studies to affect the ability of tumor cells to move and spread in the body.
WntResearch’s drug candidate Foxy-5 is a peptide that mimics the function of WNT5A with the aim of reducing the mobility and spread of cancer cells and thereby preventing metastases from occurring.
read more
Vator Securities advises Fragbite Group on 22 MSEK Directed Share Issue
Fragbite Group AB (publ) is a Swedish corporate group with a portfolio of established subsidiaries that develop, adapt and publish games and esports content within GAMING, ESPORTS and WEB3. Their products are developed for both traditional platforms – PC, mobile and console – and modern web3 platforms built on blockchain technology.
The purpose of the directed issue is mainly to finance the acquisition of Fall Damage and the continued operation of Fall Damage and the development of its tactical First Person Shooter (“FPS”) game ALARA Prime until launch.
read more
Vator Securities advises Medfield Diagnostics on 33 MSEK Rights Issue
Medfield is a medical technology company that has developed the product MD100 Strokefinder, a device powered by AI and microwave technology that can distinguish stroke patients from healthy individuals and differentiate between strokes caused by a clot and those caused by a hemorrhage.
By routing the patient directly to a stroke or trauma center, qualified treatment can be started much faster, leading to time savings, faster care, better outcomes, and lower healthcare costs. The company generates revenue through the sale of the MD100 system, software upgrades, service and maintenance, and disposable materials.
read more
9 MSEK | Q4 2023
56 MSEK | Q4 2023
22 MSEK | Q4 2023
33 MSEK | Q2 2023
